First Author: D.Inzerillo UK
Co Author(s): R. Cahill
Back to previous
To report functional and anatomical outcomes along with adverse effects of Unilateral Intravitreal Dexamethasone implant in patient with macular edema secondary to retinal vein occlusion following a retrospective review of patients treated within a large tertiary referral and Teaching Hospital based in UK.
Ophthalmology Department of University Hospital Southampton is a tertiary referral centre. The department benefits of a dedicated area of four treatment suites for the delivery of intravitreal injections of the medical retina patients in Hampshire.
A retrospective data analysis via electronic patient record system (Medisoft) of all patients who received Dexamethasone intravitreal implant in our premises. A total of 120 eyes of 120 patients underwent intravitreal Dexamethasone implant for retinal vein occlusion related macular oedema in 24 months, between 1st January 2015 and 31st January 2017. These treatments were administered by Medical Staff. patients underwent intravitreal Dexamethasone implant for retinal vein occlusion realated macular oedema in 24 months, between 1st January 2015 and 31st January 2017. These treatments were administered by Medical Staff.
The study showed that incidence of adverse effects was low and Dexamethasone intravitreal treatment is well tolerated. Visual acuity and central macular thickness outcomes were comparable to report literature.
This study provides real world evidences on the use of the 700 micrograms Dexamethasone implant in Tertiary NHS Eye Service and an example of evidence based medicine to support the steroid efficacy and tolerability in treating patient with vision deterioration due macular edema following retinal vein occlusions.